SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

Luca Malcovati, Mohsen Karimi, Elli Papaemmanuil, Ilaria Ambaglio, Martin Jädersten, Monika Jansson, Chiara Elena, Anna Gallì, Gunilla Walldin, Matteo G Della Porta, Klas Raaschou-Jensen, Erica Travaglino, Klaus Kallenbach, Daniela Pietra, Viktor Ljungström, Simona Conte, Emanuela Boveri, Rosangela Invernizzi, Richard Rosenquist, Peter J. CampbellMario Cazzola, Eva Hellström Lindberg

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15% or more bone marrow ring sideroblasts. Ring sideroblasts are found also in other MDS subtypes, such as refractory cytopenia withmultilineage dysplasia and ring sideroblasts (RCMD-RS). Ahigh prevalence of somaticmutations of SF3B1was reportedin these conditions.Toidentifymutation patterns that affect disease phenotype and clinical outcome, we performed a comprehensive mutation analysis in 293 patients with myeloid neoplasm and 1% or more ring sideroblasts. SF3B1 mutations were detected in 129 of 159 cases (81%) of RARS or RCMD-RS. Among other patients with ring sideroblasts, lower prevalence ofSF3B1mutations andhigher prevalence of mutations in other splicing factor genes were observed (P <.001). In multivariable analyses, patients with SF3B1 mutations showed significantly better overall survival (hazard ratio [HR], .37; P 5 .003) and lower cumulative incidence of disease progression (HR50.31; P5.018) comparedwith SF3B1-unmutated cases. The independent prognostic value of SF3B1 mutation was retained in MDS without excess blasts, as well as in sideroblastic categories (RARS and RCMD-RS). Among SF3B1-mutated patients, coexisting mutations in DNA methylation geneswere associated with multilineage dysplasia (P5.015) but had no effect on clinical outcome. TP53 mutationswere frequently detected in patients without SF3B1 mutation, and were associated with poor outcome. Thus, SF3B1 mutation identifies a distinct MDS subtype that is unlikely to develop detrimental subclonal mutations and is characterized by indolent clinical course and favorable outcome.

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalBlood
Volume126
Issue number2
DOIs
Publication statusPublished - Jul 9 2015

Fingerprint

Myelodysplastic Syndromes
Refractory materials
Mutation
Refractory Anemia
Hazards
Bone
Genes
DNA Methylation
Disease Progression
Bone Marrow
Phenotype
Survival
Incidence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Malcovati, L., Karimi, M., Papaemmanuil, E., Ambaglio, I., Jädersten, M., Jansson, M., ... Lindberg, E. H. (2015). SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 126(2), 233-241. https://doi.org/10.1182/blood-2015-03-633537

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. / Malcovati, Luca; Karimi, Mohsen; Papaemmanuil, Elli; Ambaglio, Ilaria; Jädersten, Martin; Jansson, Monika; Elena, Chiara; Gallì, Anna; Walldin, Gunilla; Porta, Matteo G Della; Raaschou-Jensen, Klas; Travaglino, Erica; Kallenbach, Klaus; Pietra, Daniela; Ljungström, Viktor; Conte, Simona; Boveri, Emanuela; Invernizzi, Rosangela; Rosenquist, Richard; Campbell, Peter J.; Cazzola, Mario; Lindberg, Eva Hellström.

In: Blood, Vol. 126, No. 2, 09.07.2015, p. 233-241.

Research output: Contribution to journalArticle

Malcovati, L, Karimi, M, Papaemmanuil, E, Ambaglio, I, Jädersten, M, Jansson, M, Elena, C, Gallì, A, Walldin, G, Porta, MGD, Raaschou-Jensen, K, Travaglino, E, Kallenbach, K, Pietra, D, Ljungström, V, Conte, S, Boveri, E, Invernizzi, R, Rosenquist, R, Campbell, PJ, Cazzola, M & Lindberg, EH 2015, 'SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts', Blood, vol. 126, no. 2, pp. 233-241. https://doi.org/10.1182/blood-2015-03-633537
Malcovati, Luca ; Karimi, Mohsen ; Papaemmanuil, Elli ; Ambaglio, Ilaria ; Jädersten, Martin ; Jansson, Monika ; Elena, Chiara ; Gallì, Anna ; Walldin, Gunilla ; Porta, Matteo G Della ; Raaschou-Jensen, Klas ; Travaglino, Erica ; Kallenbach, Klaus ; Pietra, Daniela ; Ljungström, Viktor ; Conte, Simona ; Boveri, Emanuela ; Invernizzi, Rosangela ; Rosenquist, Richard ; Campbell, Peter J. ; Cazzola, Mario ; Lindberg, Eva Hellström. / SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. In: Blood. 2015 ; Vol. 126, No. 2. pp. 233-241.
@article{5ae93c80f5be443cb3ae520fb33e13d0,
title = "SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts",
abstract = "Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15{\%} or more bone marrow ring sideroblasts. Ring sideroblasts are found also in other MDS subtypes, such as refractory cytopenia withmultilineage dysplasia and ring sideroblasts (RCMD-RS). Ahigh prevalence of somaticmutations of SF3B1was reportedin these conditions.Toidentifymutation patterns that affect disease phenotype and clinical outcome, we performed a comprehensive mutation analysis in 293 patients with myeloid neoplasm and 1{\%} or more ring sideroblasts. SF3B1 mutations were detected in 129 of 159 cases (81{\%}) of RARS or RCMD-RS. Among other patients with ring sideroblasts, lower prevalence ofSF3B1mutations andhigher prevalence of mutations in other splicing factor genes were observed (P <.001). In multivariable analyses, patients with SF3B1 mutations showed significantly better overall survival (hazard ratio [HR], .37; P 5 .003) and lower cumulative incidence of disease progression (HR50.31; P5.018) comparedwith SF3B1-unmutated cases. The independent prognostic value of SF3B1 mutation was retained in MDS without excess blasts, as well as in sideroblastic categories (RARS and RCMD-RS). Among SF3B1-mutated patients, coexisting mutations in DNA methylation geneswere associated with multilineage dysplasia (P5.015) but had no effect on clinical outcome. TP53 mutationswere frequently detected in patients without SF3B1 mutation, and were associated with poor outcome. Thus, SF3B1 mutation identifies a distinct MDS subtype that is unlikely to develop detrimental subclonal mutations and is characterized by indolent clinical course and favorable outcome.",
author = "Luca Malcovati and Mohsen Karimi and Elli Papaemmanuil and Ilaria Ambaglio and Martin J{\"a}dersten and Monika Jansson and Chiara Elena and Anna Gall{\`i} and Gunilla Walldin and Porta, {Matteo G Della} and Klas Raaschou-Jensen and Erica Travaglino and Klaus Kallenbach and Daniela Pietra and Viktor Ljungstr{\"o}m and Simona Conte and Emanuela Boveri and Rosangela Invernizzi and Richard Rosenquist and Campbell, {Peter J.} and Mario Cazzola and Lindberg, {Eva Hellstr{\"o}m}",
year = "2015",
month = "7",
day = "9",
doi = "10.1182/blood-2015-03-633537",
language = "English",
volume = "126",
pages = "233--241",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

AU - Malcovati, Luca

AU - Karimi, Mohsen

AU - Papaemmanuil, Elli

AU - Ambaglio, Ilaria

AU - Jädersten, Martin

AU - Jansson, Monika

AU - Elena, Chiara

AU - Gallì, Anna

AU - Walldin, Gunilla

AU - Porta, Matteo G Della

AU - Raaschou-Jensen, Klas

AU - Travaglino, Erica

AU - Kallenbach, Klaus

AU - Pietra, Daniela

AU - Ljungström, Viktor

AU - Conte, Simona

AU - Boveri, Emanuela

AU - Invernizzi, Rosangela

AU - Rosenquist, Richard

AU - Campbell, Peter J.

AU - Cazzola, Mario

AU - Lindberg, Eva Hellström

PY - 2015/7/9

Y1 - 2015/7/9

N2 - Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15% or more bone marrow ring sideroblasts. Ring sideroblasts are found also in other MDS subtypes, such as refractory cytopenia withmultilineage dysplasia and ring sideroblasts (RCMD-RS). Ahigh prevalence of somaticmutations of SF3B1was reportedin these conditions.Toidentifymutation patterns that affect disease phenotype and clinical outcome, we performed a comprehensive mutation analysis in 293 patients with myeloid neoplasm and 1% or more ring sideroblasts. SF3B1 mutations were detected in 129 of 159 cases (81%) of RARS or RCMD-RS. Among other patients with ring sideroblasts, lower prevalence ofSF3B1mutations andhigher prevalence of mutations in other splicing factor genes were observed (P <.001). In multivariable analyses, patients with SF3B1 mutations showed significantly better overall survival (hazard ratio [HR], .37; P 5 .003) and lower cumulative incidence of disease progression (HR50.31; P5.018) comparedwith SF3B1-unmutated cases. The independent prognostic value of SF3B1 mutation was retained in MDS without excess blasts, as well as in sideroblastic categories (RARS and RCMD-RS). Among SF3B1-mutated patients, coexisting mutations in DNA methylation geneswere associated with multilineage dysplasia (P5.015) but had no effect on clinical outcome. TP53 mutationswere frequently detected in patients without SF3B1 mutation, and were associated with poor outcome. Thus, SF3B1 mutation identifies a distinct MDS subtype that is unlikely to develop detrimental subclonal mutations and is characterized by indolent clinical course and favorable outcome.

AB - Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15% or more bone marrow ring sideroblasts. Ring sideroblasts are found also in other MDS subtypes, such as refractory cytopenia withmultilineage dysplasia and ring sideroblasts (RCMD-RS). Ahigh prevalence of somaticmutations of SF3B1was reportedin these conditions.Toidentifymutation patterns that affect disease phenotype and clinical outcome, we performed a comprehensive mutation analysis in 293 patients with myeloid neoplasm and 1% or more ring sideroblasts. SF3B1 mutations were detected in 129 of 159 cases (81%) of RARS or RCMD-RS. Among other patients with ring sideroblasts, lower prevalence ofSF3B1mutations andhigher prevalence of mutations in other splicing factor genes were observed (P <.001). In multivariable analyses, patients with SF3B1 mutations showed significantly better overall survival (hazard ratio [HR], .37; P 5 .003) and lower cumulative incidence of disease progression (HR50.31; P5.018) comparedwith SF3B1-unmutated cases. The independent prognostic value of SF3B1 mutation was retained in MDS without excess blasts, as well as in sideroblastic categories (RARS and RCMD-RS). Among SF3B1-mutated patients, coexisting mutations in DNA methylation geneswere associated with multilineage dysplasia (P5.015) but had no effect on clinical outcome. TP53 mutationswere frequently detected in patients without SF3B1 mutation, and were associated with poor outcome. Thus, SF3B1 mutation identifies a distinct MDS subtype that is unlikely to develop detrimental subclonal mutations and is characterized by indolent clinical course and favorable outcome.

UR - http://www.scopus.com/inward/record.url?scp=84937805127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937805127&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-03-633537

DO - 10.1182/blood-2015-03-633537

M3 - Article

C2 - 25957392

AN - SCOPUS:84937805127

VL - 126

SP - 233

EP - 241

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -